Aducanumab Data Finally Published, but Alzheimer's Experts Spot Problems

(MedPage Today) -- The long-awaited results of the twin phase III trials for aducanumab (Aduhelm), the controversial drug approved last year for early Alzheimer's disease, were published in the Journal of Prevention of Alzheimer's Disease (JPAD...